Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05056844 · ClinicalTrials.gov registry record · NA
Contrast Enhanced Spectral Mammography for the Evaluation of Pathologic Nipple Discharge
A NA study of Breast Carcinoma, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 66
- Enrollment target
- 1
- Study location
NCT05056844: Recruiting NA study of Breast Carcinoma, sponsored by M.D. Anderson Cancer Center.
NCT05056844 is a NA study of Breast Carcinoma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 66 participants, below the 770-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05056844, a NA study of Breast Carcinoma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 66 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial studies contrast enhanced spectral mammography (CESM) for the evaluation of pathologic nipple discharge. CESM is similar to standard mammography, but it includes an intravenous (by vein) injection of an iodine-based contrast, which makes tissue and blood vessels more visible in scans. The goal of this trial is to learn if CESM, is better than standard mammography in quickly and efficiently determining the cause of nipple discharge and detecting breast cancer, if present. CESM may increase the chance of finding breast cancers and lower the risk of having unnecessary biopsies.
Primary Outcome
Will be compared to low exposure (LE) images of CESM (full field digital mammogram equivalent) in detecting the causative lesion (invasive malignancy, ductal carcinoma in situ (DCIS), atypia, or papilloma) in patients with pathologic nipple discharge (PND).
Conditions Studied
Interventions
- OTHER Questionnaire Administration
- PROCEDURE Contrast Enhanced Digital Mammography
- PROCEDURE Digital Tomosynthesis Mammography
- DRUG Iodinated Contrast Agent
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2021-04-15 |
| Est. Completion | 2027-04-30 |
| Phase | NA |
What NCT05056844 shows while recruiting
NCT05056844 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, below the 770-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Breast Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Questionnaire Administration is the first listed.
NCT05056844 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05056844 about?
NCT05056844 is a clinical study titled "Contrast Enhanced Spectral Mammography for the Evaluation of Pathologic Nipple Discharge". This clinical trial studies contrast enhanced spectral mammography (CESM) for the evaluation of pathologic nipple discharge. CESM is similar to standard mammography, but it includes an intravenous (by vein) injection of an iodine-based contrast, which makes tissue and blood vessels more visible in s...
What is the current status of trial NCT05056844?
This trial is currently recruiting. It is a NA study. The enrollment target is 66 participants. The study started on 2021-04-15. Estimated completion is 2027-04-30.
What conditions does trial NCT05056844 study?
This clinical trial studies the following conditions: Breast Carcinoma.
What interventions are being tested in trial NCT05056844?
The interventions under investigation include: Questionnaire Administration (OTHER), Contrast Enhanced Digital Mammography (PROCEDURE), Digital Tomosynthesis Mammography (PROCEDURE), Iodinated Contrast Agent (DRUG).
Who is sponsoring clinical trial NCT05056844?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05056844 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05056844's enrollment target sits among peer trials
66 71st of 106 higher than 34 of 106 other Breast Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Post-treatment Supportive Service Program for the Transition Into Survivorship for Black Women Breast Cancer Survivors in Western New York
RECRUITING · NA
-
Home-based Respiratory Muscle Training for Minimizing Side Effects in Patients Undergoing Treatment for Breast Cancer
RECRUITING · NA
-
An Imaging Technology, Contrast-Enhanced Mammography, in Predicting Breast Cancer
RECRUITING · NA
-
A 3D-Printed External Breast Prosthesis for the Improvement of Patient-reported Outcomes Among Breast Cancer Patients That Underwent a Mastectomy Without Reconstruction
RECRUITING · NA
-
Cancer Genetic Testing in Ethnic Populations
RECRUITING · NA
-
Photoacoustic Imaging of the Breast in Patients With Breast Cancer and Healthy Subjects
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI